Mayo Clinic researchers report that freezing kidney tumors through percutaneous cryoablation shows promise for patients who are not good candidates for surgery. Mayo Clinic researchers report that ...

A review of 62 Mayo Clinic patients who underwent cryoablation to treat cancerous kidney tumors shows that the patients are cancer free for up to two and a half years after having had the procedure. A ...

Results were reported at a mean follow-up period of 36 months for 111 patients with 117 lesions. A summary of the key results were: In 91 patients (approximately 82%), no tumor recurrence was observed ...

Please provide your email address to receive an email when new articles are posted on . The FDA expanded the clearance of a cryoablation technology platform for the treatment of cancerous and benign ...

IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive ...

Undergoing cryoablation to treat cancerous kidney tumours could help patients remain cancer free for up to two and a half years, according to a review of 62 Mayo Clinic patients. Cryoablation, also ...

For patients with early-stage renal cell carcinomas (RCCs) that measure between 3 and 4 centimeters, a procedure that destroys the cancer by freezing – called cryoablation – yields a lower-risk of ...

Introduction: The widespread use of ultrasound and cross-sectional imaging has led to a steady increase in the incidental discovery of renal masses. Most of them are treated with partial nephrectomy ...

Small renal masses have recently been treated by cryoablation (freezing to at least −19.4 °C using liquid nitrogen or argon). Subsequent MRI or CT scans are used to evaluate the ablation, with ...

CAESAREA, Israel, Dec. 5, 2024 /PRNewswire/ -- IceCure Medical Ltd. (ICCM) (NASDAQ: ICCM) ('IceCure', 'IceCure Medical' or the 'Company'), developer of minimally-invasive cryoablation technology that ...